APA (7th ed.) Citation

Johnston, S. R. D., Chia, S., Kilburn, L. S., Gradishar, W. J., Cameron, D., Dodwell, D., . . . Bliss, J. (2012). Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors -- a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007). Cancer Research, 72(24a), 753. https://doi.org/10.1158/0008-5472.SABCS12-P2-14-01

Chicago Style (17th ed.) Citation

Johnston, S. R. D., et al. "Fulvestrant Vs Exemestane for Treatment of Metastatic Breast Cancer in Patients with Acquired Resistance to Non-steroidal Aromatase Inhibitors -- a Meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007)." Cancer Research 72, no. 24a (2012): 753. https://doi.org/10.1158/0008-5472.SABCS12-P2-14-01.

MLA (9th ed.) Citation

Johnston, S. R. D., et al. "Fulvestrant Vs Exemestane for Treatment of Metastatic Breast Cancer in Patients with Acquired Resistance to Non-steroidal Aromatase Inhibitors -- a Meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007)." Cancer Research, vol. 72, no. 24a, 2012, p. 753, https://doi.org/10.1158/0008-5472.SABCS12-P2-14-01.